Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood biomarkers could unlock sepsis mysteries

NCT ID NCT03929159

Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at small molecules called microRNAs in the blood of people with sepsis, a severe bloodstream infection. Researchers want to see if changes in these molecules can help predict who will survive. About 150 participants will provide blood samples, and their microRNA patterns will be compared to those without sepsis. The goal is to better understand the body's response to infection, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Mar 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients electively scheduled for surgical operation requiring anesthesia and hospitalization of longer than 1 day, or patients with high clinical suspicion of sepsis

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Electively scheduled for surgical operation that require general anesthesia and expected duration of hospitalization of longer than one day (for patients in Perioperative Evaluation \& Management \[POEM\]) or high clinical suspicion of sepsis by the emergency physician (for patients in emergency center) * Ability to give informed consent. If the patient is incapacitated and unable to give informed consent, the next-of-kin or a person who has the power of attorney must be present for informed consent. * For patients in the emergency center only, two or more of the following SIRS criteria: * Leukocytes \> 12,000/mm\^3 or \< 4,000/mm\^3 or \> 10% immature (band) forms, provided that no filgrastim or pegfilgrastim was administered within 30 days and no leukemia * Heart rate \> 90 beats/minute (min) * Respiratory rate \> 20 breaths/min or partial pressure of carbon dioxide (CO2) \< 32 mmHg * Oral temperature \> 38 degrees Celsius (C) or \< 36 degrees C or axillary temperature \> 37 degrees C or \< 35 degrees C Exclusion Criteria: * Inability to give informed consent or a person who has power of attorney for medical decision is not available * Being moribund (for patients in emergency center) or cancellation of surgery (for patients in POEM) * Active "Do Not Resuscitate" or "Do Not Intubate" order

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septicemia

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.